Related Experiment Video
Updated: Aug 22, 2025
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.2K
Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry
Theodore Leng1, Jason Schwartz2, David Nimke2
1Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA.
Ophthalmology and Therapy
|November 12, 2022
Summary
Geographic atrophy (GA) in dry age-related macular degeneration (dAMD) progresses faster in later stages, with lower visual acuity (VA) at baseline. Understanding dAMD progression is key for developing effective treatments.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Age-Related Macular Degeneration
Background:
- Dry age-related macular degeneration (dAMD) progression to geographic atrophy (GA) is a critical factor in late-stage disease.
- Characterizing visual acuity (VA) distribution and progression risk is essential for developing targeted dAMD treatments.
Purpose of the Study:
- To characterize the distribution of visual acuity (VA) categories in patients with dry age-related macular degeneration (dAMD).
- To evaluate the risk of VA progression based on the stage of dAMD, including geographic atrophy (GA).
Main Methods:
- Retrospective observational study using the American Academy of Ophthalmology IRIS® Registry (2016-2019).
- Analysis of 593,277 patients with dAMD, tracking VA measurements and progression to GA or neovascular AMD.
- Utilized statistical models to describe VA distribution and progression probability by disease stage.
Main Results:
- At baseline, 64.4% had mild, 29.4% intermediate, and 6.2% GA disease. Most patients had VA ≥20/63, except for those with GA with subfoveal involvement (72.0% had VA <20/63).
- Lower VA correlated with more advanced dAMD stages at baseline. Annual progression probability to GA ranged from 0.4% (mild) to 5.5% (intermediate).
- Annual progression probability to neovascular AMD was 0.5% (mild) and 8.0% (intermediate).
Conclusions:
- Patients with advanced dAMD exhibit lower baseline VA and faster progression.
- Findings underscore the significant disease burden and trajectory of dAMD.
- This study identifies critical unmet needs and opportunities for therapeutic development in dAMD.
More Related Videos
Related Concept Videos
01:25Glaucoma: Overview
691
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
691
01:22Photoreceptors and Visual Pathways
6.2K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.2K
01:27Open Angle Glaucoma: Treatment
524
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
524
01:28Angle Closure Glaucoma: Treatment
619
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
619